Emergent Biosolutions Inc
Research Emergent Biosolutions Inc (EBS) on Bullrun: market cap USD 289.33M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEBS
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 289.33M
- Financial periodQ2 2026
- RevenueUSD 226.80M
- Net income-USD 180.20M
- Free cash flowUSD 54.00M
- Gross margin57.2%
Valuation Snapshot
latest market cap is USD 289.33M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 742.90M | USD 52.60M | USD 156.80M | 56.1% | 0.93 | USD 205.40M | USD 572.10M | USD 522.60M |
| FY2024 | USD 1.04B | -USD 190.60M | USD 35.80M | 34.7% | -3.6 | USD 99.50M | USD 663.70M | USD 482.80M |
| FY2023 | USD 1.05B | -USD 760.50M | -USD 257.90M | 30.3% | -14.85 | USD 111.70M | USD 860.20M | USD 649.30M |
| FY2022 | USD 1.12B | -USD 211.60M | -USD 149.90M | 34.3% | -4.22 | USD 642.60M | USD 1.41B | USD 1.39B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 289.33M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 643.96M | 14.9 | n/a | n/a |
| 2024 | 2024-12-31 | USD 519.39M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 124.52M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 589.18M | 21.5 | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.23B | 10.2 | n/a | n/a |
About Emergent Biosolutions Inc
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Emergent Biosolutions Inc's market cap?
Emergent Biosolutions Inc's market capitalization is USD 289.33M.
What does Emergent Biosolutions Inc do?
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.